Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
Genprex Inc GNPX
$2.10
▲ +1.94%
(+$0.04)
🎈 Low Float
📅 Earnings This Week
Open
$2.11
Prev Close
$2.06
Day Range
$2.07 – $2.20
52W Range
$1.71 – $110.00
Market Cap
$1.69M
Beta
-0.92
EPS (TTM)
$-173.01
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-03-29 |
| Shares Out. | 820,000 |
| Website | genprex.com/ ↗ |
| Phone | 18777744679 |
| Employees | 13 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$4.4M |
| Free Cash Flow | -$15.6M |
| Total Assets | $17.1M |
| Total Liabilities | $2.3M |
| Equity | $14.8M |
About Genprex Inc
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Genprex Inc is a publicly traded company under the ticker symbol GNPX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2025-10-01)